Search

Research/development. Checked 2026-10-03. Preclinical/public-health phage research for AMR. Kenya research-only KE Kenya Ministry of Health describes sustainable health research including phages for AMR; no human phage therapy intake verifi

Official referral/inquiry route. Checked 2026-10-03. Individualized treatment/prevention of multidrug-resistant bacterial infection; clinician/institution-mediated supply rather than a verified independent destination clinic. Montevideo; Ur

Research/development. Checked 2026-10-03. MP101 bacteriophage treatment for P. aeruginosa pneumonia. Official August 2026 release reports completion of the sentinel cohort in first-in-human phase1 trial. Seoul; South Korea company KR Develo

Official referral/inquiry route. Checked 2026-10-03. Phase1 adults with acute P. aeruginosa pneumonia; isolate must be susceptible to MP101 and not susceptible to current antibiotic therapy per protocol. Seoul; South Korea treating-center K

Intake unconfirmed. Checked 2026-10-03. Phage strain collection, electron microscopy identification, genomic analysis and bacterial lysogeny screening; Phage Canada names Laval as a phage bank. Québec City, Québec; Canada supplier CA Refere

Official referral/inquiry route. Checked 2026-10-03. LBP-EC01 engineered CRISPR-Cas3 E. coli phage therapy for drug-resistant acute uncomplicated UTI; other pipeline programs are separate development work. Research Triangle Park, North Caro

Intake unconfirmed. Checked 2026-10-03. Clinical/translational musculoskeletal infection program and phage research; profile reports treatment protocols and research funding. Baltimore, Maryland; United States treating-center US Current fac

Intake unconfirmed. Checked 2026-10-03. Clinical program with musculoskeletal and device-associated infection experience; published LVAD case. Observational phage biobank is enrolling by invitation. Rochester, Minnesota; United States treat

Research/development. Checked 2026-10-03. Human gut microbiome and phage/IBD research expertise. Montréal, Québec; Canada research-only CA Institutional researcher/media expertise page; no human therapy patient intake verified.

Intake unconfirmed. Checked 2026-10-03. EcoActive in inactive Crohn's with intestinal adherent-invasive E. coli. New York, New York; United States treating-center US Sponsor page lists Amy.nolan@mssm.edu. Institutional listing says recruiti

Intake unconfirmed. Checked 2026-10-04. Invitation-only observational cohort for persistent NTM infection after at least 12 months of guideline-based therapy in people with cystic fibrosis; usual antibiotics continue. Earlier institutional

Case-by-case; Intake unconfirmed. Checked 2026-10-04. Personalized phage therapy research and reported clinical use; a planned study concerns recurrent urinary tract infections. Utrecht, Netherlands treating-center NL General phage treatmen

Intake unconfirmed. Checked 2026-10-03. Selected severe NTM infection with bronchiectasis treated under individualized IND; collaboration with Pittsburgh for matching. Biomarker study also covers other infections. New York, New York; United

Research/development. Checked 2026-10-03. Genomics-led phage development and microbial-defense research; clinical translation research rather than documented current patient service. Dunedin; New Zealand research-only NZ Official university

Intake unconfirmed. Checked 2026-10-03. PJI single-patient phage cases and planned dEPAnt PJI debridement/phage/antibiotic research. Ottawa, Ontario; Canada treating-center CA Program and registry show clinical research activity. No current

Intake unconfirmed. Checked 2026-10-03. Phage susceptibility testing and library support for Canadian clinicians; not a treating clinic. Winnipeg, Manitoba; Canada supplier CA Federal service description identifies a clinician-facing pilot:

Provider-listed inquiry route. Checked 2026-10-03. Helps clinicians coordinate phage matching and single-patient research in Canada. Its FAQ describes fundraising for a proposed treatment center at the University of Toronto; the center is n

Research/development. Checked 2026-10-03. Company explicitly describes itself as preclinical; ProphaLytic-Vc cholera-prevention development. Boston, Massachusetts; United States company US No clinical treatment or human trial intake route v

Research/development. Checked 2026-10-03. Developing evolved phages for drug-resistant pathogens; company reports historical emergency clinical use. Houston, Texas; United States company US Published info@phiogenpharma.com/general form is a

Case-by-case; Official referral/inquiry route. Checked 2026-10-03. Multidisciplinary compassionate use, phage discovery/manufacturing and clinical trials; AchromoPhage adults with CF and chronic Achromobacter infection is recruiting at Pitt